SANOFI PASTEUR INFLUENZA VACCINE OFFER
2021 | 2022

SCHEDULE YOUR OWN INFLUENZA VACCINE SHIPMENTS

As a select customer, you have more ways to take control of your vaccine reservations.

- Create your influenza vaccine shipment schedule
- Customize your order sizes and shipment frequency
- Manage reservations as your inventory needs change

FOLLOW THESE 3 STEPS TO CREATE YOUR OWN SHIPMENT SCHEDULE:

1. REVIEW OR CREATE YOUR RESERVATION

2. SCHEDULE YOUR SHIPMENTS

CHOOSE YOUR PREFERRED SHIPMENT FREQUENCY
Autopopulate your shipments for each presentation on your reservation:
- Once per week
- Twice per month
- Once per month
- Same as previous season

REVIEW AND ADJUST IF NEEDED
View your shipment schedule and make any adjustments to best fit your immunization plan. Continue to adjust or manage your scheduled shipments online until June 18, 2021.

No preference? Skip this step and we'll continue to schedule your shipments for you.

3. CONFIRM YOUR RESERVATION BY MARCH 31, 2021

TO LEARN MORE

Visit **VaccineShoppe.com**® | Call **1-800-VACCINE** (1-800-822-2463) | Contact your Sanofi Pasteur Representative

Please see full Important Safety Information and Indication on the back. Please see accompanying full Prescribing Information for Fluzone® Quadrivalent (Influenza Vaccine), Flublok® Quadrivalent (Influenza Vaccine), and Fluzone® High-Dose Quadrivalent (Influenza Vaccine).

SANOFI PASTEUR

IMPORTANT SAFETY INFORMATION FOR FLUZONE® QUADRIVALENT (INFLUENZA VACCINE), FLUBLOK® QUADRIVALENT (INFLUENZA VACCINE), AND FLUZONE® HIGH-DOSE QUADRIVALENT (INFLUENZA VACCINE)

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.

Before administration, please see the accompanying full Prescribing Information for Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent.

INDICATION

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are vaccines indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent is approved for use in persons 6 months of age and older. Flublok Quadrivalent is approved for use in persons 18 years of age and older. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.

To order Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent, call **1-800-VACCINE** (1-800-822-2463) or contact your Sanofi Pasteur Vaccine Specialist.

Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent are manufactured and distributed by Sanofi Pasteur Inc.
Fluzone High-Dose Quadrivalent (CPT®[a] code 90662) is a covered benefit under Medicare Part B.

Flublok Quadrivalent is manufactured by Protein Sciences Corporation, a Sanofi company, and distributed by Sanofi Pasteur Inc.
Flublok Quadrivalent (CPT® code 90682) is a covered benefit under Medicare Part B.

[a] CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

Influenza Vaccine Fluzone® High-Dose Quadrivalent

Flublok® QUADRIVALENT Influenza Vaccine

Fluzone® Quadrivalent INFLUENZA VACCINE

SANOFI PASTEUR. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofi.us
MAT-US-2019100-v1.0-10/2020

SANOFI PASTEUR